RET and non-small cell lung carcinoma: In the early phase of targeted therapy for RET fusion-positive NSCLC, the first-generation multikinase inhibitors (MKIs) with auxiliary RET activity such as sorafenib, cabozantinib, and vandetanib were commonly used.